CA2907156A1 - Toxins, compositions and related methods - Google Patents

Toxins, compositions and related methods

Info

Publication number
CA2907156A1
CA2907156A1 CA2907156A CA2907156A CA2907156A1 CA 2907156 A1 CA2907156 A1 CA 2907156A1 CA 2907156 A CA2907156 A CA 2907156A CA 2907156 A CA2907156 A CA 2907156A CA 2907156 A1 CA2907156 A1 CA 2907156A1
Authority
CA
Canada
Prior art keywords
toxin
difficile
purified
difficile toxin
toxoid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2907156A
Other languages
English (en)
French (fr)
Inventor
Mark Shieh
Mike SOIKA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SANOFI PASTEUR Inc
Original Assignee
SANOFI PASTEUR Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50489432&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2907156(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by SANOFI PASTEUR Inc filed Critical SANOFI PASTEUR Inc
Publication of CA2907156A1 publication Critical patent/CA2907156A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1051—Hexosyltransferases (2.4.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/01—Hexosyltransferases (2.4.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Dermatology (AREA)
CA2907156A 2013-03-15 2014-03-14 Toxins, compositions and related methods Abandoned CA2907156A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361793376P 2013-03-15 2013-03-15
US61/793,376 2013-03-15
PCT/US2014/029070 WO2014144594A1 (en) 2013-03-15 2014-03-14 Toxoid, compositions and related methods

Publications (1)

Publication Number Publication Date
CA2907156A1 true CA2907156A1 (en) 2014-09-18

Family

ID=50489432

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2907156A Abandoned CA2907156A1 (en) 2013-03-15 2014-03-14 Toxins, compositions and related methods

Country Status (13)

Country Link
US (1) US20160030542A1 (cg-RX-API-DMAC7.html)
EP (1) EP2970400A1 (cg-RX-API-DMAC7.html)
JP (1) JP2016519671A (cg-RX-API-DMAC7.html)
KR (1) KR20150133771A (cg-RX-API-DMAC7.html)
CN (1) CN105308066A (cg-RX-API-DMAC7.html)
AR (1) AR095668A1 (cg-RX-API-DMAC7.html)
AU (2) AU2014228983B2 (cg-RX-API-DMAC7.html)
BR (1) BR112015023469A8 (cg-RX-API-DMAC7.html)
CA (1) CA2907156A1 (cg-RX-API-DMAC7.html)
HK (1) HK1213917A1 (cg-RX-API-DMAC7.html)
SG (1) SG11201507578PA (cg-RX-API-DMAC7.html)
TW (1) TW201518316A (cg-RX-API-DMAC7.html)
WO (1) WO2014144594A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201510166YA (en) 2013-06-14 2016-01-28 Sanofi Pasteur Inc Compositions and methods of immunizing against c. difficile
CN108003224A (zh) * 2017-12-20 2018-05-08 天康生物股份有限公司 一种多杀性巴氏杆菌毒素蛋白的纯化方法
WO2023232901A1 (en) 2022-06-01 2023-12-07 Valneva Austria Gmbh Clostridium difficile vaccine
EP4658302A1 (en) 2023-02-02 2025-12-10 GlaxoSmithKline Biologicals S.A. Immunogenic composition

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071759A (en) * 1986-05-30 1991-12-10 The United States Of America As Represented By The Secretary Of The Army Hybridoma cell lines and monoclonal antibodies to clostridum difficile toxins A and B
US6969520B2 (en) * 1997-10-20 2005-11-29 Acambis Inc. Active immunization against clostridium difficile disease
JP2010534622A (ja) 2007-07-26 2010-11-11 サノフィ パストゥール リミテッド 抗原−アジュバント組成物および方法
AU2008299885C1 (en) * 2007-09-14 2015-06-25 Sanofi Pasteur Biologics, Llc Pharmaceutical compositions containing clostridium difficile toxoids A and B
GB0921288D0 (en) * 2009-12-04 2010-01-20 Health Prot Agency Therapies for preventing or suppressing clostridium difficile infection

Also Published As

Publication number Publication date
CN105308066A (zh) 2016-02-03
HK1213917A1 (zh) 2016-07-15
BR112015023469A2 (pt) 2017-07-18
WO2014144594A1 (en) 2014-09-18
WO2014144594A8 (en) 2014-11-13
US20160030542A1 (en) 2016-02-04
AU2014228983A1 (en) 2015-10-08
SG11201507578PA (en) 2015-10-29
TW201518316A (zh) 2015-05-16
AU2014228983B2 (en) 2018-04-05
AU2018204879A1 (en) 2018-07-26
KR20150133771A (ko) 2015-11-30
EP2970400A1 (en) 2016-01-20
JP2016519671A (ja) 2016-07-07
AR095668A1 (es) 2015-11-04
BR112015023469A8 (pt) 2019-12-03

Similar Documents

Publication Publication Date Title
AU2018204879A1 (en) Toxoid, compositions and related methods
CA2907154A1 (en) Toxoids, compositions and related methods
AU2004299105A1 (en) Active immunization against clostridium difficile disease
AU2002218927A1 (en) Enterohemorrhagic Escherichia coli vaccine
EP1349570A1 (en) ENTEROHEMORRAGIC i ESCHERICHIA COLI /i VACCINE
CN104487086A (zh) 无动物源的不含酒精的疫苗组合物及其制备方法
JP2016519671A5 (cg-RX-API-DMAC7.html)
US20090060904A1 (en) Vegetarian Protein A Preparation and Methods Thereof
Johnson et al. Scale-up of the fermentation and purification of the recombinant heavy chain fragment C of botulinum neurotoxin serotype F, expressed in Pichia pastoris
US20120034239A1 (en) Proteins with improved solubility and methods for producing and using same
US11926853B2 (en) Botulinum toxin producing method
US7201912B2 (en) Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis
US4702910A (en) Common antigen (PSC-A) to Pseudomonas aeruginosa which acts as an agent for pretecting Pseudomonas aeruginosa infection
CA2623176A1 (en) Protein a production and purification without using animal derived components
JPH09500537A (ja) B型インフルエンザウイルス由来のタンパク質p2の発現および精製方法
EP0282965B1 (en) Treponema hyodysenteriae antigen and uses therefor
JP3629555B2 (ja) ボルデテラからの細胞結合蛋白質の抽出
US20200123210A1 (en) Immunogenic preparations and methods against clostridium difficile infection
RU2533815C1 (ru) Способ получения протективной белоксодержащей фракции бактерий
EP0420743A1 (fr) Vaccin protecteur contre l'hémophilose porcine
KR20110029286A (ko) 어류의 연쇄상구균 백신 조성물

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190313

FZDE Discontinued

Effective date: 20220301